Deutsche Bank AG Purchases Shares of 53,469 Pharvaris N.V. $PHVS

Key Points

• Deutsche Bank acquired 53,469 Pharvaris shares worth approximately $1.85 million in the second quarter, while several other institutional investors also initiated or increased positions.
• Pharvaris shares opened at $35.32, near their 52-week high, but the company reported a quarterly loss of $0.81 per share, missing analyst expectations of a $0.75 loss.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $51.08; however, insiders sold more than 121,000 shares worth $4.27 million over the past 90 days.

Deutsche Bank AG acquired a new position in shares of Pharvaris N.V. (NASDAQ:PHVS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 53,469 shares of the company's stock, valued at approximately $1,849,000. Deutsche Bank AG owned approximately 0.08% of Pharvaris at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Persistent Asset Partners Ltd purchased a new stake in shares of Pharvaris during the 2nd quarter valued at $273,000. GSA Capital Partners LLP purchased a new position in Pharvaris in the second quarter worth $558,000. CoreCap Advisors LLC purchased a new position in Pharvaris in the second quarter worth $93,000. Seven Fleet Capital Management LP increased its stake in Pharvaris by 472.3% in the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company's stock valued at $8,947,000 after acquiring an additional 261,355 shares during the last quarter. Finally, DV Trading LLC bought a new position in Pharvaris in the first quarter valued at $4,067,000.

Pharvaris Price Performance

Shares of NASDAQ PHVS opened at $35.32 on Friday. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $38.13. The company's 50-day moving average is $34.61 and its 200 day moving average is $30.75. The stock has a market capitalization of $2.31 billion, a P/E ratio of -11.58 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Research analysts anticipate that Pharvaris N.V. will post -3.15 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on PHVS. Morgan Stanley boosted their target price on Pharvaris from $41.00 to $46.00 and gave the stock an "overweight" rating in a research report on Thursday, June 25th. Guggenheim lifted their price target on shares of Pharvaris from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. HC Wainwright restated a "buy" rating on shares of Pharvaris in a report on Friday, August 14th. Royal Bank Of Canada upped their price objective on shares of Pharvaris from $51.00 to $52.00 and gave the company an "outperform" rating in a research note on Thursday, August 13th. Finally, New Street Research set a $60.00 target price on shares of Pharvaris in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Pharvaris currently has a consensus rating of "Moderate Buy" and a consensus price target of $51.08.

Insider Buying and Selling

In related news, insider Anne Lesage sold 30,703 shares of Pharvaris stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the completion of the sale, the insider directly owned 93,969 shares in the company, valued at approximately $3,334,959.81. This trade represents a 24.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the business's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the sale, the director owned 315,167 shares of the company's stock, valued at approximately $11,185,276.83. This represents a 8.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 121,325 shares of company stock valued at $4,270,425. 11.84% of the stock is owned by company insiders.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source